PMC10024533_01
H&E staining showed histological features of high-grade serous ovarian cancer. ((A) original magnification 200x; (B) original magnification 400x).
PGPM-16-195-g0001.jpg
PMC10024533_01_PGPM-16-195-g0001.jpg
f0001
The carbohydrate antigen (CA)-125 was 1084.5 U/mL (normal range 0-35 U/mL) (Figure 1) and CA-153 was 187.9 U/mL, but other tumor markers, such as CA-199, CA-153, CEA, alpha fetoprotein, and routine blood tests were all within normal ranges. Tumors (RECIST) version 1.1 guidelines. She was then treated with the PARPi olaparib (300 mg BID) and underwent regular CA-125 monitoring tests (Figure 1). Three months later, her radiologic assessment showed a lymph node recurrence at the renal artery level between the aorta and inferior vena cava (Figure 3).  
Serum CA125 levels during the treatment course. Cycle 1-6 indicating chemotherapy cycles; 1st month, 2nd month and 3rd month indicating the time point after treatment of olaparib.
PGPM-16-195-g0002.jpg
PMC10024533_01_PGPM-16-195-g0002.jpg
f0002
Pathology analysis results identified a high-grade serous adenocarcinoma (Figure 2).
Lymph nodes recurrent between the aorta and inferior caval vein. (A and B) Contrast-enhanced CT scan shows enlarged lymph nodes between the aorta and inferior caval vein (arrow indicated); (C and D) CT showed negative findings at the end of first-line treatment.
PGPM-16-195-g0003.jpg
PMC10024533_01_PGPM-16-195-g0003.jpg
f0003
Tumors (RECIST) version 1.1 guidelines. She was then treated with the PARPi olaparib (300 mg BID) and underwent regular CA-125 monitoring tests (Figure 1). Three months later, her radiologic assessment showed a lymph node recurrence at the renal artery level between the aorta and inferior vena cava (Figure 3).  